What lessons have regulators and payers drawn from Aduhelm?
The FDA began implementing documentation reforms, CMS's restriction to clinical trials became a model for uncertain approvals, and Aduhelm now sits alongside Elevidys in debates about when surrogate endpoints are acceptable — showing how approval standards, pricing and Medicare financing are tightly connected.
The episode has had lasting effects. The FDA said it had begun implementing some of the congressional report's recommendations, including clearer documentation of interactions with drug sponsors. Public Citizen argued the FDA must ensure that future Alzheimer's reviews do not lead to the same doubts about integrity. CMS's use of coverage restricted to clinical trials became a model for handling costly drugs with uncertain benefit. The Aduhelm saga also informed debates that later surrounded other accelerated approvals, such as Sarepta's Elevidys, where senior officials likewise overruled review staff. The central lesson most observers draw is that approval standards, pricing and Medicare financing are tightly connected, and weakness in one can raise costs across the whole system.